Long-Term Assets (Quarterly)

Long-Term Assets: The sum of all assets classified as non-current.

InMed Pharmaceuticals Inc. (INM) had Long-Term Assets of $2.87M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$1.26M
Net Income	$-2.12M
Cost of Goods Sold	$1.09M
Gross Profit	$0.18M
Operating Expenses	$3.38M
Operating Income	$-2.12M
Non-Operating Income/Expense	$-0.01M
Pre-Tax Income	$-2.12M
Normalized Pre-Tax Income	$-2.12M
Income after Taxes	$-2.12M
Income from Continuous Operations	$-2.12M
Consolidated Net Income/Loss	$-2.12M
Normalized Income after Taxes	$-2.12M
EBIT	$-2.12M
EBITDA	$-2.06M
Weighted-Average Shares Outstanding (Basic)	1.10M
Weighted-Average Shares Outstanding (Diluted)	1.10M
Earnings per Share (EPS) (Basic)	$-1.94
Earnings per Share (EPS) (Diluted)	$-1.94
Balance Sheet Financials
Current Assets	$6.41M
Property, Plant, and Equipment	$1.11M
Long-Term Assets	$2.87M
Total Assets	$9.28M
Current Liabilities	$1.84M
Long-Term Debt	$0.42M
Long-Term Liabilities	$0.42M
Total Liabilities	$2.26M
Common Equity	$7.02M
Tangible Shareholders Equity	$5.36M
Shareholders Equity	$7.02M
Common Shares Outstanding	1.21M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-5.99M
Cash Flow from Investing Activities	$0.00M
Cash Flow from Financial Activities	$4.10M
Beginning Cash	$6.57M
End Cash	$4.68M
Increase/Decrease in Cash	$-1.89M
Stock-Based Compensation	$0.09M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.49
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.12
Gross Margin	13.92%
Operating Margin	-167.67%
EBIT Margin	-167.67%
EBITDA Margin	--
Pre-Tax Profit Margin	-168.12%
Profit Margin	-168.12%
Free Cash Flow	$-5.99M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.14
Inventory Turnover	1.33
Receiveable Turnover	3.43
Days Sales in Receivables	26.24
Return on Equity	-30.21%
Return on Tangible Equity	-39.57%
Return on Assets	-22.86%
Return on Investments	-28.50%
Book Value Per Share	$5.82
Free Cash Flow per Share	$-5.46
Operating Cash Flow per Share	$-5.46

Data from Zacks Investment Research, Inc.